MODULATION THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
Phase 1
Recruiting
- Conditions
- Uveal MelanomaMetastatic
- Interventions
- Drug: 38 microCi of 225Ac-MTI-201Drug: 254 microCi of 225Ac-MTI-201Drug: 19 microCi of 225Ac-MTI-201Drug: 152 microCi of 225Ac-MTI-201Drug: 750 microCi of 225Ac-MTI-201Drug: 564 microCi of 225Ac-MTI-201Drug: 4.7 microCi 225Ac-MTI-201Drug: 9.5 microCi of 225Ac-MTI-201Drug: 424 microCi of 225Ac-MTI-201Drug: 76 microCi of 225Ac-MTI-201Drug: 998 microCi of 225Ac-MTI-201Drug: 1327 microCi of 225Ac-MTI-201
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Modulation Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05496686
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
News
No news found